N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=110 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
Dilated Cardiomyopathy
Primary: Heart Failure Mortality — 8; 19 participants — p=0.01
Phase 2 N=37 PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)
Non-ischemic Dilated Cardiomyopathy
Primary: Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs) — 1; 0; 0; 1 Participants
Phase 3 N=39 Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem
Hypertrophic Cardiomyopathy
Primary: Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity — -0.06; -0.21 cm/sec…
Phase 1 N=5 Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
Dilated Cardiomyopathy
Primary: Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs. — 1 Participants
Phase 4 N=38 Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction — 42.1; 37.6 Percentage — p=0.267
N/A N=42 Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: 12-month Change in Myocardial Strain — 2.2; 1.0 percent change in heart dimension
N/A N=23 Cardiomyopathy in DMD: Lisinopril vs. Losartan
Duchenne Muscular Dystrophy (DMD) · Cardiomyopathy
Primary: Cardiac Ejection Fraction as Measured by Echocardiogram — 54.6; 55.2 percentage of blood leaving the heart
Phase 2 N=25 HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
Duchenne Muscular Dystrophy · Cardiomyopathy
Primary: Number of Participants Experiencing Any of the Adjudicated Events — 0; 0; 0; 0 Participants
Phase 2 N=26 Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs
Congestive Heart Failure · Heart Failure, Diastolic
Primary: the Safety Profile of CAP 1002; Any Subjects Experiencing Any Safety Related Events During or Post Intracoronary Delivery and During the Follow up Period. — 0; 1…
N/A N=335 Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
Phase 4 N=56 Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
Idiopathic Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months — 12; 10; 9 LVEF responders — p=0.685
Phase 1 N=48 The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy
Heart Failure · Cardiomyopathies
Primary: Change From Baseline in Markers of Cardiac Collagen Turnover (PINP) in Patients With Systolic Heart Failure and Compared With Healthy Controls. — 48.1; 48.1; 39 ng/ml…
N/A N=120 Training-induced Increased Left Ventricular Trabeculation
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
Phase 4 N=53 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
N/A N=33 Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease
Sickle Cell Disease
Primary: Frequency of the Diffuse Myocardial Fibrosis Phenotype — 5; 10; 10; 1 Participants
N/A N=30 Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
Cardiomyopathy
Primary: Change in Left Ventricular Ejection Fraction — 10.6 percentage of LVEF
Phase 2 N=153 CoQ10 and D-ribose in Patients With Diastolic Heart Failure
Heart Failure, Diastolic
Primary: Change in Health Status of Patients With HFpEF — 4.15; 26.56; 29.97; 33 Scores on a scale
N/A N=119 Early Identification of Myocardial Impairment in PBC
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
Phase 2 N=8 A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
LMNA-Related Dilated Cardiomyopathy
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 8 Participants
Phase 2 N=49 Study of AG10 in Amyloid Cardiomyopathy
Familial ATTR-CM (ATTRm-CM, or FAC) · Wild-type ATTR-CM (ATTRwt-CM)
Primary: Change in Diastolic Blood Pressure — -3.1; -3.3; -4.3; -2.6 mm Hg
Phase 3 N=133 PUFAs and Left Ventricular Function in Heart Failure
Dilated Cardiomyopathy · Heart Failure
Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
Phase 3 N=38 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)
Mitral Regurgitation
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area — 91.66; 95.74; 90.93; NA ml/m^2 — p=0.4568
Phase 2 N=12 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
Heart Failure, Congestive · Dilated Cardiomyopathy
Primary: Phase 2: Incidence of Treatment-emergent Adverse Events (TEAE) at 12 Months — 100; 100; 88.9; 92.9 percentage of participants
Phase 3 N=1,733 Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Time to All-Cause Mortality: Cohort A — 58.7; 35.8 Months — p=0.0001
Phase 3 N=441 Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations — 8595; 5071 wins — p=0.0006
Phase 2 N=41 Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Cardiomyopathy · Cardiomyopathy, Dilated
Primary: Incidence of Treatment-Emergent Adverse Events — 14; 9; 10 Participants
Phase 4 N=16 Effect of Aldosterone on Energy Starvation in Heart Failure
Heart Failure · Nonischemic Dilated Cardiomyopathy
Primary: Left Ventricular Work-metabolic Index (WMI) at Baseline — 7.4 (x10^6), mL x mm Hg/m^2
Early Phase 1 N=28 Fatty Acid Radiotracer Comparison Study in Heart Failure Patients
Heart Failure · Obesity · Type 2 Diabetes Mellitus
Primary: The Primary Endpoint is to Determine if PET/CT Measurements of Myocardial FA Metabolism Performed With [18F]FluorbetaOx Correlated With Those Performed With…